Small-Molecule TKIs: Potential Benefit in Multiple Malignancies

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Patients who received ipatasertib/fulvestrant in the intention-to-treat population achieved a median PFS of 5.32 months compared with 1.94 months in the placebo arm.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD

May 26th 2025

Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Ben Saylor

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Sasanlimab plus BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients, with notable benefit in carcinoma in situ and T1 tumors.

Rahul Banerjee, MD, FACP;Shernan Holtan, MD

March 3rd 2025

Zanubrutinib/Venetoclax Demonstrates Robust Efficacy in CLL/SLL

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

After a median follow-up of 31.2 months, the objective response rate was 97.4% among patients with CLL/SLL who were 65 or older or had comorbidities.

Roman Fabbricatore

40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data

After a median follow-up of 31.2 months, the objective response rate was 97.4% among patients with CLL/SLL who were 65 or older or had comorbidities.

Clara Lam;Zakiya Haji-Noor;Simon Collin;Lisa Okazaki;Simone T. Sredni;Miriam Haviland;Angel Valladares;Caroline Tai;Joseph Imperato

American Association for Cancer Research Annual Meeting (AACR)

Related Content

Conference

Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer

Kyle Doherty

June 1st 2025

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Patients who received ipatasertib/fulvestrant in the intention-to-treat population achieved a median PFS of 5.32 months compared with 1.94 months in the placebo arm.

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD

May 26th 2025

Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Ben Saylor

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Sasanlimab plus BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients, with notable benefit in carcinoma in situ and T1 tumors.

Rahul Banerjee, MD, FACP;Shernan Holtan, MD

March 3rd 2025

Zanubrutinib/Venetoclax Demonstrates Robust Efficacy in CLL/SLL

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

Roman Fabbricatore